Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study

L M Prens*, K Bouwman, P Aarts, S Arends, K R van Straalen, K Dudink, B Horváth, E P Prens

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

17 Downloads (Pure)


Background Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking.

Objectives To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients with HS and to identify predictors for drug survival.

Methods A retrospective multicentre study was performed in two academic dermatology centres in the Netherlands. Adult patients with HS using biologics between 2008 and 2020 were included. Drug survival was analysed with Kaplan-Meier survival curves and predictors of survival with univariate Cox regression analysis.

Results The overall drug survival of adalimumab (n = 104) at 12 and 24 months was 56 center dot 3% and 30 center dot 5%, respectively, which was predominantly determined by infectiveness. Older age (P = 0 center dot 02) and longer disease duration (P < 0 center dot 01) were associated with longer survival time. For infliximab (n = 44), overall drug survival was 58 center dot 3% and 48 center dot 6% at 12 and 24 months, respectively, and was predominantly determined by infectiveness and side-effects. Surgery during treatment was associated with a longer survival time (P = 0 center dot 01).

Conclusions Survival rates were comparable for adalimumab and infliximab at 12 months, and were mainly determined by ineffectiveness. Age, disease duration (adalimumab) and surgery (infliximab) are predictors for longer survival.

Originele taal-2English
Aantal pagina's8
TijdschriftThe British journal of dermatology
StatusPublished - 4-mei-2021

Citeer dit